

Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®)
Indication under review	Symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS)
Policy No:	APC 120
Date of Issue:	January 2016
Review Date:	January 2019
Policy Statement: Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®) is NOT recommended for prescribing for the above indication.	
Traffic Light Status	Brown
Key Points considered:	
<ul style="list-style-type: none"> • The APC did not support this treatment which was not considered clinically effective. • The APC noted that there are more effective and cost effective treatment options available for treating this condition. • This policy has been produced as a guide for GPs. Evidence and information was carefully considered and consulted upon by clinicians who concluded that this treatment is not a cost effective use of scarce NHS resources. There are situations where this policy may not apply to an individual patient due to their clinical exceptionality. This policy statement does not overrule an individual GPs clinical decision making and therefore each GP would be need to make the final decision on whether treatment is a cost-effective use of their CCG budget. 	
<small>References</small> 1 Intentionally blank 2 GW Pharma Ltd. Sativex®. Summary of Product Characteristics. Mar 2014. Available at: http://www.medicines.org.uk/emc/medicine/23262/SPC/Sativex+Oromucosal+Spray/ . 3 National Institute for Health and Clinical Excellence. Clinical Guideline in development. Multiple sclerosis: management of multiple sclerosis in primary and secondary care. Final scope. Aug 2012. Available at: http://www.nice.org.uk/nicemedia/live/13595/60372/60372.pdf . 4 The MS Trust. Multiple sclerosis information for health and social care professionals. Nov 2011. Available at: http://www.ms-trust.org.uk/downloads/ms-info-health-professionals.pdf . 5 Kingwell E, Marriott JJ, Jette N et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. <i>BMC Neurol</i> 2013; 13: 128. 6 Hirst C, Ingram G, Pickersill T et al. Increasing prevalence and incidence of multiple sclerosis in South East Wales. <i>J Neurol Neurosurg Psychiatry</i> 2009; 80 (4): 386-91. 7 Swingle RJ, Compston DA. The prevalence of multiple sclerosis in south east Wales. <i>J Neurol Neurosurg Psychiatry</i> 1988; 51 (12): 1520-4. 8 Rizzo MA, Hadjimichael OC, Preiningerova J et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. <i>Mult Scler</i> 2004; 10 (5): 589-95. 9 National Collaborating Centre for Chronic Conditions. CG8 Multiple sclerosis: full guideline. Multiple sclerosis: management of multiple sclerosis in primary and secondary care. Nov 2003. Available at: http://www.nice.org.uk/nicemedia/live/10930/46699/46699.pdf . Accessed Mar 2014. 10 Flachenecker P, Henze T, Zettl UK. Spasticity in patients with multiple sclerosis - clinical characteristics, treatment and quality of life. <i>Acta Neurol Scand</i> 2014; 129 (3): 154-62. 11 National Institute for Health and Care Excellence. Clinical Guideline 8. Multiple sclerosis: management of multiple sclerosis in primary and secondary care. Nov 2003. Available at: http://guidance.nice.org.uk/CG8 . 12 Leussink VI, Husseini L, Warnke C et al. Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity. <i>Ther Adv Neurol Disord</i> 2012; 5 (5): 255-66. 13 National Institute for Health and Care Excellence. Neurological conditions overview. Mar 2014. Available at: http://pathways.nice.org.uk/pathways/neurological-conditions . 14 Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy et al. Spasticity in adults: management using botulinum toxin. National guidelines. Jan 2009. Available at: http://www.rcplondon.ac.uk/sites/default/files/documents/spasticity-in-adults-management-botulinum-toxin.pdf . 15 National Institute for Health and Care Excellence. Clinical Guideline in development. Multiple sclerosis: management of multiple sclerosis in primary and secondary care. Apr 2014. Available at: http://guidance.nice.org.uk/CG/WaveR/115 . 16 Novotna A, Mares J, Ratcliffe S et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. <i>Eur J Neurol</i> 2011; 18 (9): 1122-31. 17 Medicines and Healthcare Products Regulatory Agency. Public Assessment Report. Decentralised Procedure. Sativex® oromucosal spray. UK/H/2462/001/DC. May 2010. Available at: http://www.mhra.gov.uk/home/groups/par/documents/websitesources/con084961.pdf . 18 Nottcutt W, Langford R, Davies P et al. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols). <i>Mult Scler</i> 2012; 18 (2): 219-28. 19 Barnes MP, Kent RM, Semlyen JK et al. Spasticity in multiple sclerosis. <i>Neurorehabil Neural Repair</i> 2003; 17 (1): 66-70. 20 Wright S, Vachova MM, Novakova I. The effect of long-term treatment with a prescription cannabis-based THC:CBD oromucosal spray on cognitive function and mood: a 12 month double blind placebo-controlled study in people with spasticity due to multiple sclerosis. Presented at 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) and the 18th Annual Conference of Rehabilitation in MS (RIMS). 4 Oct 2013. 21 Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the '5E' study. <i>Expert Rev Pharmacoecon Outcomes Res</i> 2011; 11 (2): 205-13. 22 Lu L, Pearce H, Roome C et al. Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis. <i>Pharmacoeconomics</i> 2012; 30 (12): 1157-71. 23 Flachenecker P. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany. <i>Expert Rev Neurother</i> 2013; 13 (3 Suppl 1): 15-9. 24 Slof J, Gras A. Sativex® in multiple sclerosis spasticity: a cost-effectiveness model. <i>Expert Rev Pharmacoecon Outcomes Res</i> 2012; 12 (4): 525-38. 25 Mackenzie IS, Morant SV, Bloomfield GA et al. Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database. <i>J Neurol Neurosurg Psychiatry</i> 2014; 85 (1): 76-84. 26 British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. Apr 2014. Available at: http://www.bnf.org/bnf/index.htm . 27 GW Pharma Ltd. NCT00681538. A study of the safety and effectiveness of Sativex®, for the relief of symptoms of spasticity in subjects, from phase B, with multiple sclerosis (MS). Jun 2013. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00681538 . 28 Farrar JT, Troxel AB, Stott C et al. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. <i>Clin Ther</i> 2008; 30 (5): 974-85.	
Date taken to APC:	6 th January 2016
Date Ratified by MMC on Behalf of the Board:	20 th January 2016

Berkshire West Area Prescribing Policies serve as a guide to clinicians. This does not overrule the clinical or budgetary responsibility of clinicians when considering treatment for individual patients.

Brown	Green	Amber	Red
These drugs have been reviewed and are not considered a cost effective use of scarce NHS resources	Medicines suitable for routine use. Primary care prescribers take full responsibility for prescribing	Medicines that should be initiated by a specialist and can be continued in primary care under a shared care agreement.	Medicines which should be prescribed by specialists only